Axis Research and Technologies Receives Initial Equity Funding Commitment for $1M to $5M

Share Article

Axis Research & Technologies today announced it has received a financing offer from Black Line Capital, an international investment banking firm for a $1 million to $5 million initial, common stock financing.

"My vision for Axis, is to create the nation’s top educational facility for medical device testing, surgical education, and bio tech research. “

The funds will be used to finance the commercial launch and development of their Irvine based educational facility. Additionally Axis will solidify national partners for business expansion.

Black Line Capital’s financing commitment follows over three months of negotiations, and due diligence by its principal and other experts from the medical and biotech field, as well as it’s staff of finance professionals. Accordingly, Axis anticipates closing within 45 days or less -- subject to remaining customary due diligence and documentation. The Company will announce the Closing, with full details included in a corresponding press release, and SEC filing, if deemed necessary. It is continuing to speak with other institutional investors who have expressed strong interest in participating in a follow-on financing that would reflect a stepped-up post-money valuation.

Upon receipt of the funding Axis will start pursuing national surgical education via live telecommunications programs, in addition to preparing an aggressive marketing campaign to focus on business growth and notoriety within the national medical community. It anticipates that it will be recognized as a top education facility within the year and be fully utilized as a trend setter in the testing and technology fields.

Use of proceeds includes building out the management team and resources for a highly advanced and cutting edge educational facility. The Axis facility will be outfitted with new technology designed for live educational seminars, workshops, and surgical teaching. Additionally, funding will be utilized for market exposure and client relations development.

Commenting on the funding, Axis Founder and CEO, Nick Moran, said, "We are gratified by the confidence institutional investors have in our business, the history, science and intellectual property behind it, as well our ability to quickly ramp up the multi-channel operating plan we have spent years developing."

"My vision for Axis," Mr. Moran continued, "is to create the nation’s top educational facility for medical device testing, surgical education, and bio tech research. “

Axis Research & Technologies ( is a registered California company, incorporated in 2013

Axis mission is to provide a nationally recognized elite medical research and educational facility. Axis is the largest and one of only a few specialized device testing and educational facilities in Southern California that utilizes real tissue (un-embalmed cadavers) during seminars and workshops

Safe Harbor Statement Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Axis encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at Statements released by Axis that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. The company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The company does not undertake any responsibility to update the forward-looking statements contained in this release.

At the Company

Nick Moran



Investor Relations

(818) 661-4670


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Amber Trejo
Blackline Capital Inc
+1 8186614670
Email >
Visit website